Immunocore Holdings plc

The company is a commercial-stage biotechnology firm that discovers and develops immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune diseases. Using its proprietary off-the-shelf ImmTAX platform, which combines engineered soluble T-cell receptor targeting systems with tailored immune-modulating effectors, it advances therapies across oncology, viral infections, and autoimmune indications. Its lead commercial product, KIMMTRAK, treats adult patients with unresectable or metastatic uveal melanoma. Its customer base includes cancer patients, health systems, and healthcare providers, supported by commercial third-party payors, commercial insurers, managed healthcare organizations, and government health programs.

The company's commercial operations span global markets, with KIMMTRAK approved in 39 countries and commercially launched in 30 countries, including the United States, Germany, and France. It conducts commercialization both through an in-house sales force and via regional distribution partnerships across Canada, Australia, New Zealand, Israel, Europe, Latin America, Turkey, the Middle East, North Africa, and the Commonwealth of Independent States. Drug manufacturing is outsourced to contract facilities in Denmark and Germany, with packaging completed in the Netherlands. The provided text does not state the company's headquarters.

Summary of the business section of Immunocore's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025 , we had 524 full-time employees who work primarily in the United Kingdom and the United States.”